Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity

J Pineal Res. 2011 Jan;50(1):89-96. doi: 10.1111/j.1600-079X.2010.00818.x. Epub 2010 Nov 9.

Abstract

Doxorubicin (DOX) and Trastuzumab (TRAST) are effective agents for the treatment of many neoplastic diseases. Cardiotoxicity is a major side effect of these drugs and limit their use. In this study, the possible protective effects of melatonin (MEL), mercaptoethylguanidine (MEG), or N-(3-(aminomethyl) benzyl) acetamidine (1400W) against the cardiotoxicity of DOX and TRAST were tested. Male Sprague-Dawley rats received an injection of DOX (20 mg/kg) alone or in combination with TRAST (10 mg/kg) to induce cardiotoxicity; daily treatments with MEL (10 mg/kg × 2), MEG (10 mg/kg × 2), or 1400W (10 mg/kg × 2) were begun 36 hr before and continued for 72 hr after DOX and TRAST administration. Oxidant/antioxidant indices of the cardiac tissue, namely, malondialdehyde, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), as well as serum levels of creatine phosphokinase (CK-MB) were measured. Additionally, the injury scores were evaluated histopathologically. Malondialdehyde levels were significantly higher, while SOD and GSH-Px activities were significantly reduced in rats with DOX- or DOX+TRAST-induced cardiotoxicity compared to normal values. All three treatment agents significantly reversed oxidative stress markers. Serum CK-MB levels were significantly increased after treatment with DOX and DOX+TRAST; these changes were also reversed by each of the treatments and resulted in near normal levels. Both the DOX- and DOX+TRAST-treated rats presented similar histopathologic injuries; in the animals treated with the protective agents, histologic protection of the cardiac tissue was apparent. These results suggested that MEL, MEG, as well as 1400 W are effective in preventing DOX- or DOX+TRAST-induced cardiotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology*
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Benzylamines / pharmacology*
  • Creatine Kinase / metabolism
  • Doxorubicin / pharmacology*
  • Glutathione Peroxidase / metabolism
  • Guanidines / pharmacology*
  • Heart / drug effects
  • Male
  • Malondialdehyde / metabolism
  • Melatonin / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / metabolism
  • Trastuzumab

Substances

  • Amidines
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzylamines
  • Guanidines
  • N-(3-(aminomethyl)benzyl)acetamidine
  • Malondialdehyde
  • Doxorubicin
  • Glutathione Peroxidase
  • Superoxide Dismutase
  • Creatine Kinase
  • Melatonin
  • Trastuzumab
  • 2-mercaptoethylguanidine